Prevalence of genotype-specific human papillomavirus infection and cervical neoplasia in Taiwan: a community-based survey of 10,602 women

被引:26
作者
Chen, Hui-Chi [1 ,2 ]
You, San-Lin [1 ,2 ]
Hsieh, Chang-Yao [3 ]
Schiffman, Mark [4 ]
Lin, Ching-Yu [5 ]
Pan, Mei-Hung [1 ]
Chou, Yi-Chun [2 ]
Liaw, Kai-Li
Hsing, Ann W. [4 ]
Chen, Chien-Jen [1 ,2 ]
机构
[1] Acad Sinica, Genom Res Ctr, Taipei 11529, Taiwan
[2] Natl Taiwan Univ, Grad Inst Epidemiol, Taipei 10764, Taiwan
[3] Natl Taiwan Univ Hosp, Dept Obstet & Gynecol, Taipei, Taiwan
[4] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA
[5] Taipei Med Univ, Sch Med Lab Sci & Biotechnol, Taipei, Taiwan
关键词
human papillomavirus; cervical neoplasia; genotype; impact; cohort; CYTOLOGICALLY NORMAL WOMEN; CANCER SCREENING-PROGRAM; NONVACCINE HPV TYPES; PARTICLE VACCINE; YOUNG-WOMEN; NATURAL-HISTORY; DOUBLE-BLIND; WORLDWIDE; EFFICACY; TYPE-18;
D O I
10.1002/ijc.25685
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Human papillomavirus (HPV) causes cervical neoplasia; but limited data are available from Asia. We conducted a large-scale community-based cohort study in Taiwan to estimate prevalence of genotype-specific HPV infection and cervical neoplasia. Following written informed consent, cervical cells for cytology and HPV testing were collected from 11,923 participants (aged 30-65 years old, mean 46.3) in 1991-1992. Genotyping was performed using MY11/GP6+ PCR-based HPV Blot (EasyChip) for 39 HPV types. The overall HPV prevalence was 16.2% for 10,602 eligible participants, and 13.8% for 10,190 cytologically normal participants. The most common carcinogenic types were HPV52 (2.5%), HPV16 (2.0%), HPV56 (1.8%), HPV18 (1.6%), HPV33 (1.2%), HPV58 (1.3%) and HPV39 (1.0%). Among the 56 prevalent invasive and in situ cases, HPV16 (48.2%) was most common, followed by HPV58 (25.0%), HPV52 (19.6%), HPV31 (8.9%), HPV33 (8.9%) and HPV18 (3.6%). HPV16 and HPV58 caused cytological HSIL+ at younger ages than HPV52. Approximately half of the cervical cancer cases and high-grade precursors in Taiwan could be prevented by prophylactic vaccines against HPV16 and HPV18 infection. Up to 40% more could be prevented by targeting HPV58, HPV52, HPV33 and HPV31, arguing for the introduction of vaccines including more types.
引用
收藏
页码:1192 / 1203
页数:12
相关论文
共 44 条
[21]   Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions [J].
Liaw, KL ;
Glass, AG ;
Manos, MM ;
Greer, CE ;
Scott, DR ;
Sherman, M ;
Burk, RD ;
Kurman, RJ ;
Wacholder, S ;
Rush, BB ;
Cadell, DM ;
Lawler, P ;
Tabor, D ;
Schiffman, M .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (11) :954-960
[22]   HUMAN PAPILLOMAVIRUS AND CERVICAL NEOPLASIA - A CASE-CONTROL STUDY IN TAIWAN [J].
LIAW, KL ;
HSING, AW ;
CHEN, CJ ;
SCHIFFMAN, MH ;
ZHANG, TY ;
HSIEH, CY ;
GREER, CE ;
YOU, SL ;
HUANG, TW ;
WU, TC ;
OLEARY, TJ ;
SEIDMAN, JD ;
BLOT, WJ ;
MEINERT, CL ;
MANOS, MM .
INTERNATIONAL JOURNAL OF CANCER, 1995, 62 (05) :565-571
[23]  
Liaw KL, 1997, INT J CANCER, V73, P775, DOI 10.1002/(SICI)1097-0215(19971127)73:5<775::AID-IJC27>3.0.CO
[24]  
2-3
[25]   Human papillomavirus typing with a polymerase chain reaction-based genotyping array compared with type-specific PCR [J].
Lin, Ching-Yu ;
Chao, Angel ;
Yang, Yuh-Cheng ;
Chou, Hung-Hsueh ;
Ho, Chih-Ming ;
Lin, Ruey-Wen ;
Chang, Ting-Chang ;
Chiou, Jia-Yia ;
Chao, Fang-Yu ;
Wang, Kung-Liahng ;
Chien, Tsai-Yen ;
Hsueh, Swei ;
Huang, Chu-Chun ;
Chen, Chien-Jen ;
Lai, Chyong-Huey .
JOURNAL OF CLINICAL VIROLOGY, 2008, 42 (04) :361-367
[26]   Quality assurance of genotyping array for detection and typing of human papillomavirus [J].
Lin, Ching-Yu ;
Chen, Hui-Chi ;
Lin, Ruey-Wen ;
You, San-Lin ;
You, Chiou-Mien ;
Chuang, Li-Chung ;
Pan, Mei-Hung ;
Lee, Mei-Hsuan ;
Chou, Yi-Chun ;
Chen, Chien-Jen .
JOURNAL OF VIROLOGICAL METHODS, 2007, 140 (1-2) :1-9
[27]   High prevalence of genital human papillomavirus type 52 and 58 infection in women attending gynecologic practitioners in South Taiwan [J].
Lin, H ;
Ma, YY ;
Moh, JS ;
Ou, YC ;
Shen, SY ;
ChangChien, CC .
GYNECOLOGIC ONCOLOGY, 2006, 101 (01) :40-45
[28]   Against which human papillomavirus types shall we vaccinate and screen?: The international perspective [J].
Muñoz, N ;
Bosch, FX ;
Castellsagué, X ;
Díaz, M ;
De Sanjose, S ;
Hammouda, D ;
Shah, KV ;
Meijer, CJLM .
INTERNATIONAL JOURNAL OF CANCER, 2004, 111 (02) :278-285
[29]   Epidemiologic classification of human papillomavirus types associated with cervical cancer [J].
Muñoz, N ;
Bosch, FX ;
de Sanjosé, S ;
Herrero, R ;
Castellsagué, X ;
Shah, KV ;
Snijders, PJF ;
Meijer, CJLM .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (06) :518-527
[30]   Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women:: an interim analysis of a phase III double-blind, randomised controlled trial [J].
Paavonen, Jorma ;
Jenkins, David ;
Bosch, F. Xavier ;
Naud, Paulo ;
Salmeron, Jorge ;
Wheeler, Cosette M. ;
Chow, Song-Nan ;
Apter, Dan L. ;
Kitchener, Henry C. ;
Castellsague, Xavier ;
de Carvalho, Newton S. ;
Skinner, S. Rachel ;
Harper, Diane M. ;
Hedrick, James A. ;
Jaisamrarn, Unnop ;
Limson, Genara A. M. ;
Dionne, Marc ;
Quint, Wim ;
Spiessens, Bart ;
Peeters, Pascal ;
Struyf, Frank ;
Wieting, Susan L. ;
Lehtinen, Matti O. ;
Dubin, Gary .
LANCET, 2007, 369 (9580) :2161-2170